Targeting WT1 in hematologic malignancies?

摘要

In this issue of Blood, Tawara et al report the first results of a novel treatment approach with T-cell receptor transduced autologous T cells targeting a restricted Wilms' tumor 1 (WT1)-derived epitope in patients with refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).(1)